Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Victor G Vogel Cancer Institute, Geisinger Health System, Danville, PA, USA Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Vogel VG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3998cf20a4bf48b8a83fdb8b1d1e7361
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3998cf20a4bf48b8a83fdb8b1d1e7361
record_format	dspace
spelling	oai:doaj.org-article:3998cf20a4bf48b8a83fdb8b1d1e73612021-12-02T02:54:56ZUpdate on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women1179-1314https://doaj.org/article/3998cf20a4bf48b8a83fdb8b1d1e73612011-10-01T00:00:00Zhttp://www.dovepress.com/update-on-raloxifene-role-in-reducing-the-risk-of-invasive-breast-canc-a8510https://doaj.org/toc/1179-1314Victor G Vogel Cancer Institute, Geisinger Health System, Danville, PA, USA Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use. Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemopreventionVogel VGDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 127-137 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vogel VG Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
description	Victor G Vogel Cancer Institute, Geisinger Health System, Danville, PA, USA Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use. Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemoprevention
format	article
author	Vogel VG
author_facet	Vogel VG
author_sort	Vogel VG
title	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
title_short	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
title_full	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
title_fullStr	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
title_full_unstemmed	Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
title_sort	update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/3998cf20a4bf48b8a83fdb8b1d1e7361
work_keys_str_mv	AT vogelvg updateonraloxifeneroleinreducingtheriskofinvasivebreastcancerinpostmenopausalwomen
_version_	1718402034601820160

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Ejemplares similares